ALNYLAM PHARMACEUTICALS, INC. announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran). The Company also provided its cash balance for the year ended December 31, 2023, stating that at December 31, 2023, it had preliminary cash, cash equivalents and marketable securities of approximately $2.4 billion.